Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE